Efficacy of volume-guaranteed high-frequency oscillatory ventilation in preterm infants with respiratory distress syndrome and its impact on cerebral blood flow in the middle cerebral artery.
10.7499/j.issn.1008-8830.2409030
- Author:
Yue-Yi WANG
1
;
Xue-Xu WEI
1
;
Hai-Wei YIN
1
;
Hong-Bin ZHU
1
Author Information
1. Department of Neonatology, Qinhuangdao Maternal and Child Health Hospital, Qinhuangdao, Hebei 066000, China.
- Publication Type:Journal Article
- Keywords:
Cerebral blood flow;
Efficacy;
Preterm infant;
Respiratory distress syndrome;
Volume-guaranteed high-frequency oscillatory ventilation
- MeSH:
Humans;
High-Frequency Ventilation/adverse effects*;
Infant, Newborn;
Respiratory Distress Syndrome, Newborn/physiopathology*;
Female;
Middle Cerebral Artery/physiology*;
Male;
Prospective Studies;
Cerebrovascular Circulation;
Infant, Premature
- From:
Chinese Journal of Contemporary Pediatrics
2025;27(3):286-292
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the efficacy of volume-guaranteed high-frequency oscillatory ventilation (HFOV-VG) in preterm infants with respiratory distress syndrome (RDS) and its impact on blood flow in the middle cerebral artery (MCA).
METHODS:A prospective study was conducted on 120 preterm infants with RDS who were admitted to the Department of Neonatology at Qinhuangdao Maternal and Child Health Hospital from March 2020 to December 2023. According to the mode of ventilation, the infants were divided into two groups: a conventional mechanical ventilation (CMV) group (60 infants) and an HFOV-VG group (60 infants). The two groups were compared in terms of baseline data, MCA hemodynamic parameters, complications, and outcomes.
RESULTS:Compared with the CMV group, the HFOV-VG group had significantly shorter durations of mechanical ventilation and hospital stay and a significantly higher overall response rate (P<0.05). The HFOV-VG group demonstrated significantly better peak systolic velocity, end-diastolic velocity, and mean flow velocity (P<0.05). The HFOV-VG group also exhibited significantly lower 28-day mortality rates and lower incidence rates of bronchopulmonary dysplasia and intraventricular hemorrhage than the CMV group (P<0.05).
CONCLUSIONS:HFOV-VG can effectively improve cerebral blood perfusion, reduce cerebrovascular resistance, shorten the durations of mechanical ventilation and hospital stay, and enhance overall treatment efficacy. It has significant advantages in reducing the risk of 28-day mortality, bronchopulmonary dysplasia, and intraventricular hemorrhage in preterm infants with RDS.
